210 related articles for article (PubMed ID: 20490863)
1. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
Xiong YQ; Sun HC; Zhu XD; Zhang W; Zhuang PY; Zhang JB; Xu HX; Kong LQ; Wu WZ; Qin LX; Tang ZY
J Cancer Res Clin Oncol; 2011 Mar; 137(3):505-12. PubMed ID: 20490863
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
[TBL] [Abstract][Full Text] [Related]
4. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma.
Jung KH; Rumman M; Yan H; Cheon MJ; Choi JG; Jin X; Park S; Oh MS; Hong SS
Phytother Res; 2018 Oct; 32(10):2034-2046. PubMed ID: 29972254
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
[TBL] [Abstract][Full Text] [Related]
6. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
7. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
[TBL] [Abstract][Full Text] [Related]
8. Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma.
Wu YH; Cao JG; Xiang HL; Xia H; Qin Y; Huang AJ; Xiao D; Xu F
World J Gastroenterol; 2009 Apr; 15(14):1744-50. PubMed ID: 19360918
[TBL] [Abstract][Full Text] [Related]
9. Survivin depletion inhibits tumor growth and enhances chemosensitivity in hepatocellular carcinoma.
Or YY; Chow AK; Ng L; Fan ST; Yau TC; Poon RT; Pang RW
Mol Med Rep; 2014 Oct; 10(4):2025-30. PubMed ID: 25070628
[TBL] [Abstract][Full Text] [Related]
10. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.
Kang HG; Wang BZ; Zhang J; Liu MR; Li YX
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):197-203. PubMed ID: 27863926
[TBL] [Abstract][Full Text] [Related]
11. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
12. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma.
Guo XL; Li D; Sun K; Wang J; Liu Y; Song JR; Zhao QD; Zhang SS; Deng WJ; Zhao X; Wu MC; Wei LX
J Mol Med (Berl); 2013 Apr; 91(4):473-83. PubMed ID: 23052483
[TBL] [Abstract][Full Text] [Related]
14. [Effect of inhibiting survivin expression with antisense oligodeoxynucleotides on sensitivity of hepatocellular carcinoma cell lines HepG2 and HepG2/ADM to adriamycin].
Dai DJ; Lu CD; Guo JM; Zhang J
Ai Zheng; 2005 Aug; 24(8):951-7. PubMed ID: 16086872
[TBL] [Abstract][Full Text] [Related]
15. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
16. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
17. PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
Katsura Y; Wada H; Murakami M; Akita H; Hama N; Kawamoto K; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S517-26. PubMed ID: 23508585
[TBL] [Abstract][Full Text] [Related]
18. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling.
Tan ZB; Fan HJ; Wu YT; Xie LP; Bi YM; Xu HL; Chen HM; Li J; Liu B; Zhou YC
J Ethnopharmacol; 2019 Mar; 232():62-72. PubMed ID: 30553869
[TBL] [Abstract][Full Text] [Related]
19. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway.
Yan H; Jung KH; Kim J; Rumman M; Oh MS; Hong SS
Biomed Pharmacother; 2018 Feb; 98():134-141. PubMed ID: 29253760
[TBL] [Abstract][Full Text] [Related]
20. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
